Literature DB >> 20832193

[Interest of real-time PCR Xpert MRSA/SA on GeneXpert(®) DX System in the investigation of staphylococcal bacteremia].

A Scanvic1, L Courdavault, J-P Sollet, F Le Turdu.   

Abstract

AIM OF THE STUDY: Recently, a rapid, fully automated real-time PCR test has become available for detection of Staphylococcus aureus in positive blood cultures, Xpert MRSA/SA blood culture. This study was defined to evaluate the use of this product in our hospital setting to assist in optimizing antibiotic treatment.
MATERIALS AND METHODS: Over a period of 18months (from February 2008 to July 2009), 51 positive blood cultures were examined for Staphylococcus using the Xpert MRSA/SA assay on the GeneXpert(®) System. The PCR results were transferred to the clinician as soon as available. The presence of empirical antibiotic therapy was noted and modified if necessary after discussions between the clinician and the infectious disease specialist.
RESULTS: Twenty-three blood bottles were positive for S. aureus, two were resistant to methicillin. Twenty-eight were coagulase negative staphylococci. No discrepancy between identification (S. aureus) and methicillin resistance was observed. Thirty-two samples had clinically significant bacteremia (23 S. aureus and nine coagulase negative staphylococci). Sixteen (50%) of these patients had received inappropriate antibiotic therapy (11 without antibiotic therapy, five with betalactam antibiotics). For these patients, an appropriate antibiotic therapy was prescribed according to these results. Sixteen patients had adequate empirical antibiotic therapy at the time of receiving the PCR result. Among these 16 patients, eight switches were performed from broad-spectrum treatment to a more restrictive antistaphylococcal treatment. Of the 19 patients with a nonclinically relevant coagulase negative staphylococci infection, four were already on antibiotics for other infections and these treatments were not modified. Empirical treatment could be avoided in 13 patients who had a clinical presentation consistent with staphylococcal bacteremia (multiple sores, history of carrying methicllin-resistant or susceptible S. aureus infection, presence of intravascular material or prosthesis).
CONCLUSION: The real-time PCR Cepheid Xpert MRSA/SA on GeneXpert(®) DX System has become an essential tool in our laboratory enhancing the reports of positive blood cultures for staphylococci. This test is fast (50min) and reliable. It allows optimization of antibiotic therapy in hospital.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20832193     DOI: 10.1016/j.patbio.2010.07.016

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  5 in total

1.  Impact of results of a rapid Staphylococcus aureus diagnostic test on prescribing of antibiotics for patients with clustered gram-positive cocci in blood cultures.

Authors:  Jane Davies; Claire L Gordon; Steven Y C Tong; Robert W Baird; Joshua S Davis
Journal:  J Clin Microbiol       Date:  2012-04-04       Impact factor: 5.948

2.  Sensitivity and Specificity of a Novel Colony Characteristic for Determination of Methicillin-Resistant Staphylococcus aureus.

Authors:  Apeksha N Agarwal; Steven D Dallas; Daniel D Mais
Journal:  Cureus       Date:  2022-06-17

Review 3.  Advances and challenges in biosensor-based diagnosis of infectious diseases.

Authors:  Mandy L Y Sin; Kathleen E Mach; Pak Kin Wong; Joseph C Liao
Journal:  Expert Rev Mol Diagn       Date:  2014-02-13       Impact factor: 5.225

Review 4.  Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns.

Authors:  Catia Cilloniz; Ignacio Martin-Loeches; Carolina Garcia-Vidal; Alicia San Jose; Antoni Torres
Journal:  Int J Mol Sci       Date:  2016-12-16       Impact factor: 5.923

Review 5.  Impact of MRSA on the Military Medical Service and Diagnostic Point-of-Care Options for the Field Setting.

Authors:  Hagen Frickmann
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2018-06-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.